Affymetrix Takes Aim at Illumina with Rollout of New Axiom Exome Array | GenomeWeb

By Justin Petrone

Affymetrix this week began shipping its Axiom Exome Genotyping Arrays with the hope that the new chip's content and custom design options can capture what appears to be strong demand in the marketplace for such products.

"We have exceeded our content expectations on the product; it is now available, in inventory, and we are taking orders," Andy Last, executive vice president of Affy's genetic analysis and clinical applications business unit, told BioArray News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.